Riccardo Palmisano is Board Member at Agc Biologics, a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. Graduated in Medicine at Parma University, his career in the Italian pharmaceutical industry started in 1986 at Farmitalia Carlo Erba (1986). He then moved on to Gruppo Menarini (1988) where he contributed to the development and internationalisation of the first Italian pharmaceutical Group, becoming Director of the Pharmaceutical Division Italy in 1993 and General Manager at Lusofarmaco in 1995. His career in multinational companies started in 2000: he set up the Italian branch of Shire Pharmaceutical (2000), then he was appointed Vice President Commercial Retail Market in GlaxoSmithKline Verona (2003) and, lastly, Vice President & General Manager Italy at Genzyme (2005), a U.S. biotech company specialized in research and development of orphan drugs for rare diseases. After the acquisition of Genzyme by Sanofi he was appointed Director of Business Strategy and Development at Sanofi Italia (2012-2013). Until 2020 he held the position of CEO of MolMed, now part of AGC Biologics. During his career, he successfully launched a large number of important products in many therapeutic areas, in both retail and hospital markets, participated and supported several international projects, and successfully negotiated pricing and reimbursement for several innovative drugs with the Italian Authorities. In 2008, he joined Assobiotec, becoming Vice President, responsible for biotech pharma and health, in 2010. In 2016, was appointed President of Assobiotec. He was recently appointed Vice President of the Lombard Cluster of Life Sciences in Assolombarda.